Editor 
By LINDA BOYLE
“It is the love of money that has the potential to exterminate – to render extinct – the entire human race.” ~ Michael Rupert
Dr. Anthony Fauci, at a Feb 1, 2021 White House Covid briefing, said: “The best way to fight the new variants that are spreading is to get people vaccinated as quickly and expeditiously as possible throughout the country.”
He concluded by saying that by vaccinating the entire population as soon as possible would “prevent the emergence of variants here in our country.”
Five or six more boosters since then and Covid-19 continues to mutate. Now there is a push for a yearly shot, much like the flu shot mentality.
It seems, however, most Americans aren’t buying this “you must get this jab or you will die” propaganda anymore. Drug companies such as Moderna aren’t making big bucks any longer. In fact, the total revenue for Moderna in fourth quarter 2023 was $2.8 Billion—a decrease of $5.1 Billion from the same time frame in 2022. This is a dramatic 43% decline.
But have no fear — the government is gearing up to stop other diseases and preparing for the new diseases that are just around the corner. The government is also working on older diseases that need a makeover with modern vaccine technology. It plans to use your tax dollars to fund Big Pharma so the income stream can flow again.
Moderna is ecstatic to report the first mRNA “vaccine” for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for folks over 60.
It was approved even though it is only 78% effective against two of the RSV symptoms—cough and fever.
This newly developed RSV vaccine still needs to get approved by a panel of “experts.” Moderna’s CEO has announced this approval will give the company a much-needed shot for new revenue. It’s revenue that will make up for the losses due to people not taking all those Covid-19 boosters.
The new mRNA drug for RSV has the brand name of mRESVIA. The company says because it is made by an mRNA process, it has the potential to be more effective than any conventional shots.
What does this approval mean financially for Moderna? “Analysts on average forecast sales for Moderna’s RSV vaccine of $340 million in 2024, growing to $830.5 million the following year, according to LSEG data.”
Moderna is also going to receive some more good news. The U.S. government is ready to make an agreement with the company that will fund a “late-stage trial” of Moderna’s mRNA bird flu vaccine.
There is concern that the bird flu has been contracted by a grand total of three Americans, none of whom died.
This bird flu vaccine funding would be through the Biomedical Advanced Research and Development Authority (BARDA) with an expectation of tens of millions of dollars to be funneled to Moderna for these trials. This deal may include a commitment by the government to buy these vaccines for the H5N1 Bird flu if the taxpayer-funded trials are successful.
Not wanting to leave Pfizer out of this lucrative deal, the government is also in talks with Pfizer to develop mRNA vaccines to target the H5 family of bird flu viruses. The Financial Times stated the ability of these two companies to add to the U.S. pandemic stockpile would be a big boon for them; both companies’ shares fell as the demand waned for Covid-19 jabs.
Pfizer announced it is ready to “deploy the company’s capabilities to develop a vaccine for strategic stockpiles.”
Despite the very low threat of bird flu, the World Health Organization is sounding the alarm, as is FDA Commissioner Robert Califf. Califf has warned this potential bird flu pandemic could have a “mortality rate of up to 25%.” The CDC, however, says it is still a low risk and if contracted by a person it can be easily treated.
Other public health experts stated this prediction is a bit over the top and even “farcical.”
Still others ponder if this potential “fear-mongering” is related to profit possibilities.
It seems as if Big Pharma is gearing up and their eyes light up over the profits that could be made.
The National Institutes of Heath is also interested. Afterall, NIH scientists made $71 million in royalties from the last go-around. About $690 million went to the subagency called the National Institute of Allergy and Infectious Diseases — the one Dr. Fauci used to run. Add to this the $400 million of Covid royalties NIH got from Pfizer and Moderna. It is unclear if the $71 million is in addition or part of this $400 million settlement. NIH isn’t saying.
Follow the money. Follow the greed. Sadly, many people in power are more concerned with that than they are with your wellbeing.
Will we fall for this again? It’s hard to say. There are still those among us wearing the face mask—N-95 no less, and over their beards, or with their noses hanging out, virtue signaling to the rest of us.
Linda Boyle, RN, MSN, DM, was formerly the chief nurse for the 3rd Medical Group, JBER, and was the interim director of the Alaska VA. Most recently, she served as Director for Central Alabama VA Healthcare System. She is the director of the Alaska Covid Alliance.
